Haleon (HLN) Stock Analysis – A Fundamental Overview

By Susan Ramirez • Monday, February 17 15:07 • Permanent Link

Haleon marked a -2.4% change today, compared to -0.0% for the S&P 500. Is it a good value at today's price of $9.71? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
Haleon belongs to the Consumer Discretionary sector, which has an average price to earnings (P/E) ratio of 22.6 and an average price to book (P/B) of 3.19
The company's P/B ratio is 5.34
Haleon has a trailing 12 month Price to Earnings (P/E) ratio of 29.4 based on its trailing 12 month price to earnings (EPS) of $0.33 per share
Its forward P/E ratio is 23.1, based on its forward earnings per share (EPS) of $0.42
Over the last four years, Haleon has averaged free cash flows of $1.55 Billion, which on average grew -11.6%
HLN's gross profit margins have averaged 61.0 % over the last four years and during this time they had a growth rate of 0.4 % and a coefficient of variability of 4.69 %.
Haleon has moved 17.3% over the last year compared to 22.9% for the S&P 500 -- a difference of -5.6%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.